logo
Send Message
Hefei Home Sunshine Pharmaceutical Technology Co.,Ltd
products
products
Home > products > API Active Pharmaceutical Ingredient > Altrenogest CAS 850-52-2 API Active Pharmaceutical Ingredient

Altrenogest CAS 850-52-2 API Active Pharmaceutical Ingredient

Product Details

Place of Origin: China

Brand Name: Sunshine

Certification: ISO,COA

Model Number: 850-52-2

Payment & Shipping Terms

Minimum Order Quantity: Negotiation

Price: Negotiation

Packaging Details: Aluminum Foil Bag, Drum

Delivery Time: 7-15DAY

Payment Terms: D/A,L/C,D/P,Western Union,T/T,MoneyGram

Supply Ability: G,KG,TON

Get Best Price
Highlight:

Altrenogest CAS 850-52-2

,

CAS 850-52-2

Appearance::
Slightly Yellow Powder
CAS NO::
850-52-2
Molecular Formula::
C21H26O2
Molecular Weight::
310.43000
EINECS NO::
212-703-1
MDL NO::
MFCD00867855
Appearance::
Slightly Yellow Powder
CAS NO::
850-52-2
Molecular Formula::
C21H26O2
Molecular Weight::
310.43000
EINECS NO::
212-703-1
MDL NO::
MFCD00867855
Altrenogest CAS 850-52-2 API Active Pharmaceutical Ingredient

Product Description:

Product Name: Altrenogest CAS NO: 850-52-2


Synonyms:

17-allylt-renbolone;

ru2267;

drc6246;


Chemical & Physical Properties:

Appearance: Slightly yellow powder

Assay :≥99.00%

Density: 1.15 g/cm3

Boiling Point: 495.6℃ at 760 mmHg

Melting Point: 120℃

Flash Point: 210.1℃

Refractive Index: 1.594

Storage Condition: 0-6℃


Safety Information:

HS Code: 2937290090


Altrenogest (INN, USAN, BAN) (brand name Regumate), also known as allylt-renbolone, is a s-teroidal progestin that is widely used in veterinary medicine to suppress estrus in animals. Altrenogest(A35957; RU2267) is a progestogen structurally related to veterinary s-teroid t-renbolone.Target: Progesterone ReceptorAltrenogest is a progestogen structurally related to veterinary s-teroid t-renbolone. Treatment of embryo-recipient mares with altrenogest appears to be beneficial in extending the degree of donor-recipient synchrony required for successful embryo transfer. Altrenogest treatment also seems to be conductive to pregnancy maintenance in recipients experiencing luteal dysfunction. The oil and gel altrenogest preparations are equally effective in modulating estrous behavior and time to estrus and ovulation. Altrenogest treatment started late in diestrus appears to result in a high incidence of ovulation during treatment and when luteolysis and ovulation occur during treatment; the subsequent luteal phase is frequently prolonged due to failure of regression of the CL.


If you are interested in our products or have any questions, please feel free to contact us!


Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.